10X Genomics Inc (TXG) — Cash Flow-to-Debt Ratio
10X Genomics Inc (TXG) has a Cash Flow-to-Debt Ratio of 0.18x as of September 2025, meaning its operating cash flow of $43.21 Million could theoretically repay 0% of its total liabilities ($241.03 Million) in one year. See 10X Genomics Inc (TXG) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
10X Genomics Inc Cash Flow-to-Debt Ratio (2017–2024)
Historical debt coverage capacity for 10X Genomics Inc across 8 annual periods. Also explore 10X Genomics Inc (TXG) net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for 10X Genomics Inc (2017–2024)
Year-by-year debt coverage analysis for 10X Genomics Inc. For market capitalisation and broader financial context, see 10X Genomics Inc market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.03x | $6.66 Million | $208.50 Million | ▲ +147.1% |
| 2023 | -0.07x | $-15.20 Million | $224.10 Million | ▲ +55.0% |
| 2022 | -0.15x | $-33.61 Million | $223.24 Million | ▼ -41.8% |
| 2021 | -0.11x | $-21.37 Million | $201.26 Million | ▲ +90.7% |
| 2020 | -1.15x | $-217.90 Million | $190.27 Million | ▼ -714.6% |
| 2019 | 0.19x | $34.63 Million | $185.84 Million | ▲ +184.0% |
| 2018 | -0.22x | $-76.41 Million | $344.30 Million | ▼ -290.2% |
| 2017 | -0.06x | $-10.70 Million | $188.12 Million | — |